Академический Документы
Профессиональный Документы
Культура Документы
ByYonseiGSISMastersCandidates:NicoleFitch,MAin
blablabla
BrianGleason,MAin
GlobalStudies
RoxannaWilson,MAin
KoreanStudies
MillenniumDevelopmentGoal(MDG)8EAim:
PharmaceuticalCommunication
TheaimofMDGgoal8Eisincooperationwithpharmaceutical
companies,provideaccesstoaffordableessentialmedicinesin
developingcountries.
YonseiUniversityGraduateSchoolofInternationalStudies
(GSIS)
NewMillenniumPolicyForum(NMPF)Aim:PolicyMemo
TheNewMillenniumPolicyForum(NMPF)whichisinplace
tofacilitatediscussiononthecurrentissuessurroundingunmet
MDGs.TheMDG8EPolicyMemo,inassociationtothe
NMPF,addressesexistinggoalimpedimentsandrecommendsa
policythatincludeshowaninternationalcommunitycan
reconciletheinterestsbetweenlargepharmaceuticalcompanies
andhumanrightstohealthanddevelopmentinrelationto
providingaccesstoaffordableandessentialdrugs.(aka.
Overview)
InthedevelopmentoftheMemo,literaturereviewsrelatedto
MDGgoal8Ewereundertaken.However,theevidence
gatheringandconstructionofthePolicyMemowasmuchmore
variedthanonlyliteraturereview;ourteamalsoinvestigated
realworldapplicationthroughcasestudiesanddiscussedour
policyproposalwithimportantstakeholders.(aka.Methodology
<thiswontbeadded>)
TheMemomakestwomainrecommendationsaimedatpolicy
makersanddecisiontakersatinternational,nationalandlocal
level.
Structure(ornameTableofContents?)
ThePolicyMemoisdividedinto3mainparts:
Part1Background,existingproblemsandneedfor
action
Theexistingproblemsaredividedintofourdimensions:
(referencetoppt)
1a.Pharmaceuticalindustrysrole
1b.Sustainabledevelopmentandintellectual
propertyrights
1c.Cultureandideologicalimpediments
1d.Flawedhealthsystems
Part2Evidenceandevaluation
Part3PrinciplesandPolicy
Principlesexplainhowtheresearchinggroup
arrivedattheconclusionandtherationaleusedtodevelop
thepolicy.
ThePrinciplesaredividedintothreedimensions:
3a.Healthassustainabledevelopment
3b.Allactorstoworkinconcert
Policy
ThePolicyisdividedintotwodimensions:(Whateverwe
putontheslide)
3c.InformationNetwork
3d.DevelopmentthroughBusiness
Part1
Background:
In evaluating the efficacy and progress towards goal 8E, the lack
of benchmarks or measurable deliverables was apparent. The
focus seemed too broad for the time frame, which now seems to
be far too optimistic and unrealistic. How can one know if the
goal has been met or when it could be expected? Thus, our
group has focused on the issues pertaining to the persistence of
untreated diseases in the developing world and the system
responsible for provision of the corresponding medication.
ExistingProblems:
1a.Pharmaceuticalindustrysrole
One major issue is the lack of R&D targeting diseases prevalent
in the developing world, which highlights the role of market
forces in determining the priorities of the pharmaceutical
industry. With little or no incentive to conduct expensive
poor. These rights extend beyond the individual and apply even
to traditional knowledge and processes, and the rights can be
held by a group of people or whole community who could then
benefit from the licensing.
The Institute for Trade Standards and Sustainable Development
(ITSSD) presents data that demonstrate the importance of
intellectual property right protection in the fight for sustainable
development. Without the assurance that rights will be
protected, would-be innovators have no incentive to innovate
(Hunt and Kosla 2). This presents a problem to the international
community that lacks an easy solution. In the rush for
development and in an attempt to meet the MDGs by 2015,
states can take advantage of the TRIPS clause permitting the use
of licenses in certain emergency situations (Joseph 428). This
trend of pushing the pace of development beyond the capacity of
the international community to draft IP agreements is risking the
destruction of any progress made so far toward an international
agreement (Kogan).
1c.Culturalandideologicalimpediments
Colonizationandexploitationbywesterncountriesmay
influencefeelingstowardWesternideologyandmedicinein
developingcountries.Othermisunderstandingsalsooccurwhen
patientsarenotabletounderstandtheimportanceofdosage
managementorsideeffectseitherbylinguisticorcultural
differences(Wilhelm,616).Distrustofforeigncompanypower
andextremecautiontoprotectthelocaleconomyFearby
westernworldthinkingethicsinquestion.(expoundRoxy)
1d.Flawedhealthsystem
Health systems in emerging markets suffer from a variety of
ails, such as corruption and poor infrastructure, which prevent
even the pharmaceutical products that are injected into the
market from reaching those who most need them (Cohen,
Mrazek, et al 445 - 449). <Something about dosage here Nicole?
Lets explain the above in more detail> Developing countries are
also dealing with the issue of counterfeit and substandard drugs.
The WHO puts the annual amount of counterfeit drug sales close
to 35-40 billion dollars a year and that one in three drugs in the
worldwide market is counterfeit. Pfizer alone estimates its
Strategicactionneeded
Actors:
Multinationalbodies
Civilsocietyorganizations
Government
NonGovernmentOrganizations(NGOs)
PharmaceuticalIndustryandRepresentatives
Media
WorkplacesandInstitutions
Practitionersinglobalhealth
World Intellectual Property Organization (WIPO)
People
Policy:(needstobeexpounded)
3c.HealthInformationNetwork(HIN?)
In order to rectify the lack of benchmarks or measurable
deliverables in Goal 8E, we advocate the creation of a Goal 8E
Health Information Network for every developing country. Each
country is a complex system that requires a unique
understanding of context, monitoring and evaluation. Thus, the
HIN in each country will gather and centralize all of the relevant
health data pertinent to Goal 8E and provide specific, constantly
updated data regarding the diseases that are affecting the
population, the amount of medication required to combat these
diseases, and the estimated costs of treatment. Although some of
correspondencefromthosewhodonothaveinternetaccessand
conducttheHealthInformationNetworksearchforthem
directly.Thispersonwillthenrelaytheneededinformationback
tothepersonwhomadetheinquiry.
3d.DevelopmentthroughBusiness
In order to promote further collaboration, we suggest turning
current World Bank and IMF funding that is distributed to each
countrys health budget into grants or programs proposed and
implemented by pharmaceuticals. Such programs could involve
R&D, professional development of local medical practitioners,
or the creation of regulated drug production facilities within the
state receiving the funds. This puts the impetus for improving
access to drugs for the worlds poor into the hands of those who
stand to profit from the development of the country: the
pharmaceuticals and other organizations receiving the grants.
This new collaboration between grant recipients and developing
states will give each incentive to see to the improved health of
the population and to protect intellectual property rights,
including the increased regulation of generic drug producers
within the developing countries.
WorksCited
Bailey, Michael, Ruth Mayne and Mohga Smith. Fatal Side
Effects: Medicine Patents under the Microscope. Oxfam Great
Britain: London, 2001, 5, 15-17
Behrens, R. H., Shakoor, O., and Taylor R. B. Assessment of the
incidence of substandard drugs in developing countries.
Tropical Medicine and International Health Volume 2 No. 9,
September 1997.
Bennett,Sara.,Bhutta,Zulfigar.,Evans,Timothy.,Hyder,Adnan
A.,Mills,Anne.,Pang,Tikki.,Pielemeier,NancyR.andTravis,
Phyllida. "OvercomingHealthSystemsConstraintstoAchieve
theMillenniumDevelopmentGoals."Lancet364.9437(2004):
9006.Print.
Brudon P. Comparative analysis of national drug policies in 12
countries. WHO/DAP/97.6. Action Programme on Essential
Drugs. Geneva: World Health Organization, 1997: 114.
Capie,Susan."OutlookonChina'sPharmaDevelopment2004."
JournalofGenericMedicines2.3(2005):2128.Print.
Chaturvedi,Sachin."ExploringInterlinkagesbetweenNationaland
SectoralInnovationSystemsforRapidTechnologicalCatchUp:
CaseofIndianBiopharmaceuticalIndustry."Technology
Analysis&StrategicManagement19.5(2007):64357.Print.
Cohen, J. C., M. Mrazek, et al. "Tackling Corruption in the
Pharmaceutical Systems Worldwide with Courage and
Conviction." Clin Pharmacol Ther 81(3): 445-449.
Dawar, Sandrine. Trade and Human Rights. Diss. The Fletcher
School, Tufts University, 2004, 18
Dennis,Suzanna,andElaineZuckerman."MappingMultilateral
DevelopmentBanks'SpendingonReproductiveHealthandHIV
andAIDS."Gender&Development16.2(2008):287300.Print.
Etkin,NinaL.""SideEffects":CulturalConstructionsand
ReinterpretationsofWesternPharmaceuticals."Medical
anthropologyquarterly6.2(1992):pp.99113.Print.
Evans, Tony. A human right to health? Third World Quarterly
Volume 23 (2002) 211
Falkenberg, Torkel and Tomson, Goran. The World Bank and
Pharmaceuticals. Health Policy and Planning Volume 15, Issue
1, pp. 52-58.
InnovationandGenerateEconomicGrowth.Ideas,
InnovationandPatentsICFAI
LawBooksDivision,ICFAIUniversityPress,Andhra
Pradesh,India.(2008)pp.
103133.
Lagomarsino,Gina,etal."PublicStewardshipofMixedHealth
Systems."Lancet374.9701(2009):15778.Print.
Leisinger,KlausM.,andKarinM.Schmitt."AccesstoHealthcare
andthePharmaceuticalSector."CambridgeQuarterlyof
HealthcareEthics20.2(2011):30925.Print.
LobLeyvt,Julian.VaccineCoverageandtheGAVIAlliance
ImmunizationServicesSupportInitiative.TheLancet
373.9659(2009):Page209.Print.
Meier, Benjamin M. and Fox, Ashley M. Development as Health:
Employing the Collective Right to Development to Achieve the
Goals of the Individual Right to Health. Human Rights
Quarterly Volume 30, Number 2, May 2008, pp. 259-355
Mitra, Pramit. India at the Crossroads: Battling the HIV/AIDS
Pandemic. The Washington Quarterly Volume 27:4. Autumn
2004. pp. 95-107
Perks,Carol,Toole,MichaelJ.andKhamlaPhouthonsy."District
HealthProgrammesandHealthSectorReform:CaseStudyin
theLaoPeople'sDemocraticRepublic."BulletinoftheWorld
HealthOrganization84.2(2006):1328.Print.
Richards,EdwardP.TheRoleofMedicalandPublicHealth
ServicesinSustainableDevelopment."Washington,DC,USA":
EnvironmentalLawInstitute,2002.Web.
Runyowa,Tavengwa.MedicinesPatentPoolAimsToIncrease
AccessToHIVDrugsInDevelopingCountries.Intellectual
PropertyWatch:March10,2011.Web.
Sachs,Jeffrey.TheEndofPoverty:EconomicPossibilitiesforOur
Time.PenguinBooks2006:7490.Print.
Tarullo, Daniel. WTO, Developing Countries, and Regionalism.
American Enterprise Institute, Washington. 3 Oct. 2006
Thomas, Caroline. Trade policy and the politics of access to
drugs. Third World Quarterly. 23 (2002): 257.
Vernon,JohnA.,JosephH.^.Golect,andW.Keener^Hughen.
"TheEconomicsofPharmaceuticalPriceRegulationand
Importation:RefocusingtheDebate."AmericanJournalofLaw
&Medicine32.2/3(2006):17592.Print.
Witty,Andrew."NewStrategiesforInnovationinGlobalHealth:A
PharmaceuticalIndustryPerspective."Healthaffairs30.1
(2011):11826.Print.
World Health Organization. WHO global burden of disease: 2004
update. 2008. Web. Accessed March 25, 2011.